BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Coronary artery disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for coronary artery disease: 270 (164 sponsors; 36 newly posted in the last 180 days, 10 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 10.2, rank 65 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 5, Phase 2 28, Phase 3 25, Phase 4 7, N/A 202.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Novartis Pharmaceuticals NVS9P4 2, P2 1, P3 5, NA 132
Amgen AMGN5P3 2, P4 2, NA 110
Eli Lilly and Company LLY4P3 2, P2 1, P1 120
ECRI bv2P3 1, NA 100
Tasly Pharmaceutical Group Co., Ltd2P3 1, P2 111
CeleCor Therapeutics1P3 100
CSL Behring1P3 100
Daiichi Sankyo1P3 100
DalCor Pharmaceuticals1P3 100
EBI Anti Sepsis BV1P3 100
iVascular S.L.U.1P3 101
Jiangsu vcare pharmaceutical technology co., LTD1P3 101
Moleac Pte Ltd.1P3 100
NewAmsterdam Pharma NAMS1P3 100
Novo Nordisk A/S NVO1P3 100
Pulnovo Medical (Wuxi) Co., Ltd.1P3 100
Seismic Pharmaceuticals Operations LLC1P3 100
Sinotau Pharmaceutical Group1P3 100
Tasly Pharmaceuticals, Inc.1P3 101
Genoss Co., Ltd.13NA 1301
Abbott Medical Devices6NA 601
CoreAalst BV6P4 1, NA 500
Abiomed Inc.5NA 510
Biosensors Europe SA5EARLY_P1 1, NA 410
Biotronik AG5NA 501

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3United Therapeutics UTHRNCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseasenrolling by invitation1000
2026-12 est.P1/P2GE HealthcareNCT04604782 A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric PatientsMyocardial Ischemia; Coronary Artery Diseaserecruiting54
2026-12 est.P2Pulmovant, Inc.NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILDPulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovasrecruiting20
2026-12-30 est.P3Jiangsu vcare pharmaceutical technology co., LTDNCT06577519 Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)recruiting1000
2026-12-30 est.P2XyloCor Therapeutics, Inc.NCT07118449 Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABGCoronary Artery Disease (CAD)not yet recruiting116
2026-12-31 est.P1/P2Tasly Pharmaceutical Group Co., LtdNCT07265349 A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart FailureCoronary Artery Bypass Grafting (CABG); Chronic Heart Failure; Chronic Ischemic Cardiomyopathyrecruiting51
2027-01-11 est.P3AstraZeneca AZNNCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventCardiovascular Diseaseactive not recruiting3103
2027-01-13 est.P3iVascular S.L.U.NCT05952206 Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet TherapyCoronary Artery Diseaseactive not recruiting2312
2027-01-16 est.P3Novartis Pharmaceuticals NVSNCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesAcute Coronary Syndromeactive not recruiting305
2027-01-29 est.P3Novo Nordisk A/S NVONCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackCardiovascular Risk; Acute Myocardial Infarction (AMI)active not recruiting10000
2027-02-08 est.P2AbcentraNCT06927739 Focused Orticumab Research for Treating Inflammation in Coronary ArteriesAcute Coronary Syndromes; Coronary Arterial Disease (CAD); Inflammation; Heart Disease; Myocardial Irecruiting240
2027-02-14 est.P1/P2Hudson BiotechNCT07487363 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDAtherosclerotic Cardiovascular Diseases; Endothelial Dysfunctionrecruiting80

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3NewAmsterdam Pharma NAMSNCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseAtherosclerotic Cardiovascular Diseaseactive not recruiting9541
2026-10-26 est.P3Novartis Pharmaceuticals NVSNCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression inCoronary Artery Diseaseactive not recruiting610
2026-10-02P3MedTrace Pharma A/SNCT05134012 RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)Coronary Artery Diseasecompleted232
2026-10-01 est.P2Research Institute of Geroprotective TechnologiesNCT07397351 Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent ImplantationCoronary Artery Diseaserecruiting180
2026-10 est.P2Beijing Inno Medicine Co., Ltd.NCT07311330 Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile DysfunctionAtherosclerotic Cardiovascular Disease (ASCVD); Erectile Dysfunctionrecruiting40
2026-08-01P1/P2Implicit BioscienceNCT06678074 Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMISTEMI; STEMI (ST Elevation MI); STEMI - ST Elevation Myocardial Infarction (MI); Stent Implantationcompleted7
2026-07-22P2Beijing Inno Medicine Co., Ltd.NCT06700720 YN001-004 in Patients With Coronary Atherosclerosis in AustraliaCoronary Artery Disease; Coronary Atherosclerotic Diseaseterminated3
2026-07-16P3Novartis Pharmaceuticals NVSNCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCardiovascular Disease and Lipoprotein(a)completed8323
2026-07-02P2ResoTher PharmaNCT06465303 A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)ST Elevation Myocardial Infarctioncompleted66
2026-05-26P2Pulmovant, Inc.NCT06635850 A Study of Mosliciguat in PH-ILDPulmonary Hypertension; Interstitial Lung Disease; Lung Diseases; Vascular Diseases; Cardiovascular active not recruiting135

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "coronary artery disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.